Editorial: M et ALD and Risk of Gastrointestinal Cancer—What Can We Learn From Japan? Authors' Reply

Documenti analoghi

• Gastrointestinal Cancer Risk in Steatotic Liver Diseases: MASLD , MetALD and ALD
  di: Nobuharu Tamaki, et al.
  Pubblicazione: (2025)
• Cardiometabolic criteria as predictors and treatment targets of liver‐related events and cardiovascular events in metabolic dysfunction‐associated steatotic liver disease
  di: Nobuharu Tamaki, et al.
  Pubblicazione: (2024)
• Long‐term clinical outcomes in steatotic liver disease and incidence of liver‐related events, cardiovascular events and all‐cause mortality
  di: Nobuharu Tamaki, et al.
  Pubblicazione: (2024)
• Editorial: Risk of Incident Type 2 Diabetes and Prediabetes in Patients With Direct Acting Antiviral‐Induced Cure of Hepatitis C Virus Infection
  di: Nobuharu Tamaki, et al.
  Pubblicazione: (2025)
• Editorial: MetALD and Risk of Gastrointestinal Cancer—What Can We Learn From Japan?
  di: Hannes Hagström, et al.
  Pubblicazione: (2025)